KRAS and neoplasm: Therefore, usage of miR-200c in a therapeutic approach may be superior to that of a siRNA against KRAS. As demonstrated by several reports, this miRNA has multiple targets [53], which regulate crucial events for tumor progression, e.g. epithelial-mesenchymal transition (EMT), acquisition of stem-like properties or therapy resistance (Figure 5).